BWFA
CYTK icon

Baltimore-Washington Financial Advisors’s Cytokinetics CYTK Stock Holding History

Baltimore-Washington Financial Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-200
Closed -$1K – 294
2014
Q2 		$1K Buy
+200
New +$1.22K ﹤0.01% 269

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baltimore-Washington Financial Advisors's CYTK Position: Q3 2014 in Review

Baltimore-Washington Financial Advisors sold out of Cytokinetics (CYTK) in Q3 2014, closing a stake of 200 shares — an estimated $1K sold.

Baltimore-Washington Financial Advisors first reported a position in CYTK in Q2 2014 and held it in 1 quarter. The position peaked at $1K in Q2 2014. 85 funds tracked by Wall St. Rank hold CYTK as of Q3 2014.

  • Baltimore-Washington Financial Advisors reported no remaining Cytokinetics position as of Q3 2014 after selling out during the quarter.
  • Baltimore-Washington Financial Advisors sold 200 Cytokinetics shares in Q3 2014, an estimated $1K.
  • Baltimore-Washington Financial Advisors first reported a position in Cytokinetics in Q2 2014 and held it in 1 quarter.
  • Baltimore-Washington Financial Advisors's Cytokinetics position peaked at $1K in Q2 2014.
  • 85 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2014.

Based on Baltimore-Washington Financial Advisors's 13F filing for Q3 2014, filed 29 Oct 2014.